These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
245 related items for PubMed ID: 15695306
21. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D. Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078 [Abstract] [Full Text] [Related]
22. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, Vencovský J. Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624 [Abstract] [Full Text] [Related]
23. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F. Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004 [Abstract] [Full Text] [Related]
24. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group. Arthritis Rheum; 2007 Sep; 56(9):3096-106. PubMed ID: 17763439 [Abstract] [Full Text] [Related]
25. Infliximab therapy in established rheumatoid arthritis: an observational study. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254 [Abstract] [Full Text] [Related]
26. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. Haraoui B, Cameron L, Ouellet M, White B. J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747 [Abstract] [Full Text] [Related]
27. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, Devogelaer JP, Houssiau FA. Ann Rheum Dis; 2004 Sep; 63(9):1069-74. PubMed ID: 15308515 [Abstract] [Full Text] [Related]
28. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF. J Rheumatol; 2005 Feb; 32(2):252-5. PubMed ID: 15693084 [Abstract] [Full Text] [Related]
29. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F. Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989 [Abstract] [Full Text] [Related]
30. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O. Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502 [Abstract] [Full Text] [Related]
31. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group. Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186 [Abstract] [Full Text] [Related]
32. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE. Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612 [Abstract] [Full Text] [Related]
33. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G. Panminerva Med; 2006 Jun; 48(2):129-35. PubMed ID: 16953150 [Abstract] [Full Text] [Related]
34. Dose intensification with infliximab in patients with rheumatoid arthritis. Berger A, Edelsberg J, Li TT, Maclean JR, Oster G. Ann Pharmacother; 2005 Dec; 39(12):2021-5. PubMed ID: 16288073 [Abstract] [Full Text] [Related]
35. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, Nagano A. Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492 [Abstract] [Full Text] [Related]
36. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P. Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189 [Abstract] [Full Text] [Related]
37. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Voulgari PV, Venetsanopoulou AI, Exarchou SA, Alamanos Y, Tsifetaki N, Drosos AA. Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499 [Abstract] [Full Text] [Related]
38. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D. Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336 [Abstract] [Full Text] [Related]
39. [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study]. Caramaschi P, Canestrini S, Biasi D, Carletto A, Scambi C, Scarperi A, Bambara LM. Recenti Prog Med; 2002 Jan; 93(1):19-24. PubMed ID: 11850995 [Abstract] [Full Text] [Related]
40. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register. Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]